Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has shared an announcement.
QIAGEN has disclosed that the Dutch financial markets regulator AFM notified the company of a substantial holding in its shares by BlackRock, Inc. as of January 29, 2026. According to the filing, BlackRock holds a total capital interest of 10.79% and voting rights of 11.95% in QIAGEN, through a mix of direct and indirect holdings in ordinary shares and derivatives such as contracts for difference, spread across numerous BlackRock entities. The announcement underscores the significant role of a major global asset manager in QIAGEN’s shareholder base, potentially reinforcing the company’s profile in international capital markets, while QIAGEN emphasizes it is not responsible for the accuracy of the AFM-reported data.
The most recent analyst rating on (QGEN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, is a life sciences and diagnostics company whose shares are listed on multiple European exchanges as well as the NYSE and Swiss markets. The company operates in regulated markets and targets global investors through its listings in Frankfurt, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate, SIX and BX Swiss.
Average Trading Volume: 1,843,471
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.1B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.